WEBHELP
Webhelp, a leading global customer experience BPO player, has announced that this year it has achieved its highest global growth since inception, with operations now spanning more than 60 countries and with close to 125,000 people employed globally. Webhelp also won more than 50 industry awards this year, was recognized as a leader in the Gartner Magic Quadrant for Customer Service BPO, and earned top ratings in Customer Experience globally by Analyst Everest Group.
Across the year, Webhelp expanded in 24 new locations and six new countries – Thailand, Bosnia Herzegovina, Ghana, Israel, North Macedonia, and China – with a further 18 new site openings in existing locations across the United States, Latin America, Asia Pacific, and Europe, Middle East and Africa. Webhelp also experienced very strong client growth in 2022, onboarding over 240 new logo clients across the world, and welcoming more than 25,000 game-changers to the company. In line with increased demand, Webhelp continued to bolster hybrid and remote working through its Webhelp Anywhere proposition to deliver ultimate flexibility and scalability to clients and meet evolving employee work preferences.
“Growth is a team sport, and every single one of our people has had a part to play in this extraordinary year for Webhelp. We pride ourselves on the stellar work our game-changers deliver on behalf of our clients and look forward to continuing this trend in 2023, investing further in tech and people, to continue to provide the best possible solutions to our clients and their customers,” said Olivier Duha, CEO and Co-Founder of Webhelp.
Webhelp successfully completed a number of notable acquisitions and strategic investments, including the acquisition of Grupo Services in LATAM, the leading Brazilian providers of digitally enabled Customer Experience. In EMEA, Webhelp also joined forces with Uitblinqers to strengthen its position in the Dutch market and made additional investments with Gobeyond Partners, with the creation of a Nudge practice – a strategic unit that leverages behavioral economics to help organizations drive the best possible outcomes, through influencing customer behaviors.
“The past few years have taught us that connection and humanity are more important than ever. I’m incredibly proud to be at the helm of a fast-growing company that is leading the way in tech-enabled, human-centric Customer Experience,” continues Olivier Duha.
Webhelp has also been focusing on strengthening its sustainability and environmental social governance (ESG) practices. 12% of its workforce have been hired via an award-winning impact sourcing program, which includes hiring disadvantaged youth, reintegration initiatives to help female prisoners get into work, and an ecosystem that supports migrant and refugee employability. This year, Webhelp also partnered with SGS, the leading certification company, on a long-term initiative to safeguard frontline health and well-being.
Webhelp’s growth strategy underpins its desire to serve as a strategic blue ocean partner, leveraging a combination of global reach and hyper local expertise to unlock new value for its clients. Webhelp’s solutions and services are designed to be relevant and valuable for both digital native clients and businesses seeking to transform CX and drive strategic value and differentiation from it.
In 2023, Webhelp will continue its strategic growth, expanding further in new and current key locations across the world, including APAC, EMEA, and the Americas, as well as investments in people, technology, and innovation.
###
About Webhelp
Webhelp designs, delivers, and optimizes unforgettable human experiences for today’s digital world – creating game-changing customer journeys. From sales to service, content moderation to credit management, Webhelp is an end-to-end partner across all B2C and B2B customer journeys. Its over 110,000 passionate employees across more than 60 countries thrive on making a difference for the world’s most exciting brands. Webhelp is currently owned by its management and Groupe Bruxelles Lambert (Euronext: GBLB), a leading global investment holding, as of November 2019. For more information on Webhelp, visit Webhelp.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221220005345/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SIAL Paris 2026 : The Entire Food Industry in One Place – An Unmissable Event for Professionals8.12.2025 09:00:00 CET | Press release
SIAL Paris 2026 is more than ever the world’s must-attend food industry event With less than a year to go, SIAL Parisonce again stands as a key international gathering for food industry professionals. With 85% of exhibition space already booked, the show demonstrates very strong momentum and appeal. SIAL Paris will welcome 295,000 professionals from 200 countries across a stunning 280,000 m² of exhibition space, covering all sectors of the food industry. Innovation at the core of global food transformation In a context marked by major demographic, environmental and geopolitical challenges, SIAL Paris stands as THE hub where innovation drives action, business, and transformation. It brings across all sectors’ ideas, projects, and solutions that address today’s challenges, all while inspiring food business around the world. As in every edition, the show will offer a unique immersive experience, facilitating meaningful meetings and business opportunities. SIAL Paris serves as the global i
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 08:00:00 CET | Press release
Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8th International Conference, taking place January 14-17 2026 in Madrid, Spain. Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.”
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release
L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release
The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
